Iron, HFE mutations, and hepatocellular carcinoma: Is hepatic iron a carcinogen?

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 4, 2003, Pages 246-248

  Ioannou, George N ^a,b   Kowdley, Kris V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; IRON;

CANCER INCIDENCE; CANCER RISK; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; FOLLOW UP; GENE; GENE MUTATION; GENOTYPE; HEMOCHROMATOSIS; HFE GENE; HUMAN; IRON DEPLETION; IRON STORAGE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PHENOTYPE;

EID: 0141989861     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(03)00126-5     Document Type: Editorial

References (24)

1. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
2. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JF Jr. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-162.
3. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724.
4. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-1535.
5. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218.
6. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U, Halvorsen TB, Smethurst HB, Sagen E, Bjerve KS. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-1115.
7. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-651.
8. Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F, Valla D, Belghiti J, Degott C, Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-204.
9. Goh J, Callagy G, McEntee G, O'Keane JC, Bomford A, Crowe J. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. Eur J Gastroenterol Hepatol 1999;11:915-919.
10. Kohler HH, Hohler T, Kusel U, Kirkpatrick CJ, Schirmacher P. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver: a case report. Pathol Res Pract 1999;195:509-513.
11. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 1990;11:566-569.
12. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-566.
13. Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol 1992;80:235-241.
14. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997;112:882-888.
15. Chapoutot C, Esslimani M, Joomaye Z, Ramos J, Perney P, Laurent C, Fabbro-Peray P, Larrey D, Domergue J, Blanc F. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 2000;46:711-714.
16. Ganne-Carrie N, Christidis C, Chastang C, Ziol M, Chapel F, Imbert-Bismut F, Trinchet JC, Guettier C, Beaugrand M. Liver iron is predictive of death in alcoholic cirrhosis: A multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. Gut 2000;46:277-282.
17. Gordeuk VR. African iron overload. Semin Hematol 2002;39:263-269.
18. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-1566.
19. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996;87:3470-3476.
20. Hellerbrand C, Pöppl A, Hartmann A, Schölmerich J, Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastrol Hepatol 2003;1:279-284.
21. Lauret E, Rodriguez M, Gonzalez S, Linares A, Lopez-Vazquez A, Martinez-Borra J, Rodrigo L, Lopez-Larrea C. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002;97:1016-1021.
22. Cimburova M, Putova I, Provaznikova H, Horak J. Hereditary hemochromatosis: detection of C282Y and H63D mutations in HFE gene by means of guthrie cards in population of Czech Republic. Genet Epidemiol 2002;23:260-263.
23. Nielsen P, Carpinteiro S, Fischer R, Cabeda JM, Porto G, Gabbe EE. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 1998;103:842-845.
24. Muting D, Kalk JF, Fischer R, Wiewel D. Spontaneous regression of oesophageal varices after long-term conservative treatment: Retrospective study in 20 patients with alcoholic liver cirrhosis, post-hepatitic cirrhosis and haemochromatosis with cirrhosis. J Hepatol 1990;10:158-162.